Director, Translational Medicine at Vor Bio

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

PhD, MD, or MD/PhD in a relevant scientific discipline (e.g., immunology, oncology, neuroscience, pharmacology)
10+ years of experience in translational medicine, clinical development, or related R&D roles in biotech/pharma
Proven track record of advancing drug candidates through late phase clinical development (Phase II–III)
Deep understanding of biomarker science, clinical trial design, and regulatory considerations
Strong leadership, communication, and cross-functional collaboration skills
Experience with omics technologies, bioinformatics, and data integration is highly desirable
Preferred Attributes
Therapeutic area expertise in autoimmune, immunology, and/or rare diseases
Experience working in fast-paced, innovative biotech environments
Familiarity with regulatory submissions (e.g., IND, CTA, BLA) and companion diagnostics development

Responsibilities

Strategic Leadership: Define and execute the translational medicine strategy across therapeutic programs, aligning with corporate R&D goals
Biomarker Development: Oversee the identification, validation, and implementation of predictive, pharmacodynamic, and safety biomarkers
Clinical-Preclinical Integration: Translate preclinical findings into clinical hypotheses and study designs; ensure bidirectional flow of insights between lab and clinic
Cross-Functional Collaboration: Partner with discovery, preclinical toxicology, clinical development, regulatory, bioinformatics, and commercial teams to drive data-informed decision-making
External Engagement: Build and maintain relationships with academic collaborators, CROs, consortia, and regulatory bodies to advance translational objectives
Data Strategy: Guide the integration of multi-omics, imaging, and real-world data to inform patient stratification and therapeutic response
Team Leadership: Mentor and lead a high-performing team of translational scientists and project leads

Skills

Translational Medicine

Biomarker Development

Strategic Leadership

Preclinical Research

Clinical Development

R&D Pipeline

BAFF/APRIL Inhibitors

Autoimmune Diseases

Vor Bio

Develops targeted therapies for blood cancers

About Vor Bio

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.

Cambridge, MassachusettsHeadquarters

2015Year Founded

$147.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Risks

Significant YTD price decline of -62.76% may affect investor confidence.

Key clinical trial data updates are not expected until 2025, causing uncertainty.

Increased competition from companies like Editas Medicine poses potential conflicts.

Differentiation

Vor Bio focuses on protecting healthy cells while targeting cancerous ones.

The company specializes in innovative treatments for blood cancers like AML.

Vor Bio's approach aligns with the rise of personalized medicine.

Upsides

Recent $55.6M funding supports clinical trials and extends cash runway to 2025.

FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.

Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

Land your dream remote job 3x faster with AI

Try Jobo Free